# ADAPT-BLADDER (NCT03317158)

> Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

No report yet. It can be ordered.

- Drugs tested: durvalumab plus gemcitabine plus docetaxel; durvalumab plus tremelimumab plus gemcitabine plus docetaxel; intravesical NAI plus gemcitabine plus docetaxel
- Indication: BCG-unresponsive, BCG-relapsing, high-risk BCG-naive non-muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03317158
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Noah Hahn, M.D.
- Conditions: Urothelial Carcinoma; Bladder Cancer
- Interventions: Durvalumab (Cohort 1-3); External Beam Radiotherapy (EBRT); Bacillus Calmette-Guérin (BCG); Gemcitabine; Docetaxel; Tremelimumab; Durvalumab (Cohort 4/5); To be determined; Intravesical NAI (Cohorts 6-7); Subcutaneous NAI (Cohort 8)
- Enrollment: 186
- Primary outcome: Phase 1: Determine the recommended phase 2 dose (RP2D) from BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
- Primary outcome: Phase 2: Determine the complete response rate within individual phase 2 expansion cohorts of BCG-unresponsive, BCG-relapsing/persistent, and high-risk BCG-naïve NMIBC subjects treated with each study regimen

## Indexed commentary on ADAPT-BLADDER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- Podcasts: 3
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=adapt-bladder-nct03317158

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03317158", "email": "<work email>"}; the inbox owner confirms by the emailed link.